Erschienen in:
17.07.2023 | Melanoma
Great Debate: Limb Infusion for Melanoma: A Thing of the Past?
verfasst von:
Kristen E. Rhodin, MD, MHS, Douglas S. Tyler, MD, Jonathan S. Zager, MD, Georgia M. Beasley, MD, MHS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 11/2023
Einloggen, um Zugang zu erhalten
Excerpt
Melanoma remains a prevalent form of skin cancer, with nearly 98,000 estimated new cases in 2023.
1 Approximately half of these patients will present with disease isolated to an extremity, and 4–10% of patients will experience locoregional recurrence after oncologic resection.
2‐4 A unique locoregional presentation termed “in-transit melanoma” (ITM) occurs when tumor deposits arise in the dermal and subdermal lymphatics between the primary tumor and the draining nodal basin. In-transit melanoma is heterogeneous in the size and number of lesions, in addition to its tumor biology, disease progression, and outcomes.
2,5 At presentation, up to 40% of patients with ITM have concurrent nodal disease, and 50–75% ultimately experience distant metastases.
5‐7 Given its association with aggressive disease, in the current American Joint Commission on Cancer (AJCC) staging system (8th edition), ITM is designated as at least stage IIIB.
8 …